Quality of life profiles in the first years of rheumatoid arthritis: Results from the EURIDISS longitudinal study

Suurmeijer, Th.P.B.M.; Waltz, Millard; Moum, T.; Guillemin, Françis; Sonderen, van Eric; Briançon, Serge; Sanderman, Robbert

doi:10.1002/1529-0131(200104)45:2<111::aid-anr162>3.3.co;2-5

Cited by 35 publications

(43 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The primary clinicopathologic concept of arthritis is that it comprises inflammation and resultant cartilage destruction in the joints (36), and the latter factor has a great physiologic impact on joint function that in turn negatively affects prognosis and/or quality of life (37,38). Several studies of RA have suggested that overproduction of proinflammatory cytokines (e.g., TNF␣ and IL-6) by synovial cells during the phase of accelerated proliferation and local accumulation of primed macrophages at the site of lesions induces production of additional proinflammatory mediators and differentiation of osteoclasts (and/or chondroclasts) from a monocyte/macrophage lineage through the NF-B pathway (39)(40)(41)(42).…”

Section: Discussionmentioning

confidence: 99%

Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis

Hamada¹,

Torikai²,

Kuwazuru³

et al. 2008

Arthritis & Rheumatism

108

111

View full text Add to dashboard Cite

Objective. Tissue hypoxia is closely associated with arthritis pathogenesis, and extracellular high mobility group box chromosomal protein 1 (HMGB-1) released from injured cells also has a role in arthritis development. This study was thus undertaken to investigate the hypothesis that extracellular HMGB-1 may be a coupling factor between hypoxia and inflammation in arthritis.Methods. Concentrations of tumor necrosis factor ␣, interleukin-6, vascular endothelial growth factor, lactic acid, lactate dehydrogenase, and HMGB-1 were measured in synovial fluid (SF) samples from patients with inflammatory arthropathy (rheumatoid arthritis and pseudogout) and patients with noninflammatory arthropathy (osteoarthritis). The localization of tissue hypoxia and HMGB-1 was also examined in animal models of collagen-induced arthritis (CIA). In cellbased experiments, the effects of hypoxia on HMGB-1 release and its associated cellular events (i.e., protein distribution and cell viability) were studied.Results. In SF samples from patients with HMGB-1-associated inflammatory arthropathy (i.e., samples with HMGB-1 levels >2 SD above the mean level in samples from patients with noninflammatory arthropathy), concentrations of HMGB-1 were significantly correlated with those of lactic acid, a marker of tissue hypoxia. In CIA models in which the pathologic phenotype could be attenuated by HMGB-1 neutralization, colocalization of HMGB-1 with tissue hypoxia in arthritis lesions was also observed. In cell-based experiments, hypoxia induced significantly increased levels of extracellular HMGB-1 by the cellular processes of secretion and/or apoptosis-associated release, which was much more prominent than the protein release in necrotic cell injury potentiated by oxidative stress.Conclusion. These findings indicate that tissue hypoxia and its resultant extracellular HMGB-1 might play an important role in the development of arthritis.High mobility group box chromosomal protein 1 (HMGB-1) is a nuclear architectural protein that is released from necrotic cells (1) and/or secreted from activated macrophages (2,3). It has been identified as a mediator of endotoxin-induced lethality (2,4) and a causative factor in arthritis (3,5-7), acting, at least in part, as a proinflammatory cytokine (1-11). Engagement of the receptor for advanced glycation end products (RAGE) by extracellular HMGB-1 triggers activation of proinflammatory signaling pathways (10,11), such as those resulting in elaboration of reactive oxygen inter-

show abstract

Section: Discussionmentioning

confidence: 99%

Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis

Hamada¹,

Torikai²,

Kuwazuru³

et al. 2008

Arthritis & Rheumatism

108

111

View full text Add to dashboard Cite

show abstract

“…The World Health Organization Quality of Life assessment (WHOQOL) group has defined QoL as 'Individuals' perception of their position in life in the context of the culture and the value system in which they live and in relation to their goals, expectations, standards and concerns' [2]. The WHOQOL definition of QoL focuses attention on the patient's perspective on QoL and assumes an evaluation of several life domains by the patient [3,4]. This definition of QoL has influenced the definitions used in many other studies [1,[4][5][6].…”

Section: Introductionmentioning

confidence: 99%

The Relative Contribution of Domains of Quality of Life to Overall Quality of Life for Different Chronic Diseases

et al. 2004

Self Cite

View full text Add to dashboard Cite

The relative contribution of domains of quality of life to overall quality of life for different chronic diseases R. Arnold, R.; Ranchor, Adelita V.; Sanderman, Robbert; Kempen, G.I.J.M.; Ormel, Johan; Suurmeijer, T.P.B.M. Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. AbstractThis study examined the contribution of the quality of life (QoL) domains physical, social and psychological functioning to the explanation of overall QoL. Various disorders may differentially affect QoL domains due to disease-specific factors and, consequently, the relationship between QoL domains and overall QoL may vary between diseases. We therefore studied this relationship for several diseases as well as the differential impact of these diseases on QoL. The present study had a cross-sectional design. We selected patients (aged 57 years and older) with one of the following eight chronic medical conditions: lung disorder, heart condition, hypertension, diabetes mellitus, back problems, rheumatoid arthritis, migraine, or dermatological disorders. The total group of respondents included 1457 patients and 1851 healthy subjects. Regression analyses showed that the domain of psychological functioning contributed to overall QoL for all disorders, whereas physical and social functioning contributed to overall QoL for some disorders. Differences were found between most patient groups and healthy subjects with respect to physical functioning; with respect to social and psychological functioning some groups differed from the healthy group. Explanations for the findings and implications for clinical practice are discussed.

show abstract

“…The high prevalence of fatigue and its chronicity in RA patients is a major source of disability and diminished quality of life [5,7,8]. It is described as a sensation of weakness, lack of energy or tiredness, or even a sustained exhaustion associated with a decreased capacity for physical and mental work [5,35].…”

Section: Discussionmentioning

confidence: 99%

Determination of the minimal clinically important difference for seven fatigue measures in rheumatoid arthritis

Pouchot¹,

Kherani²,

Brant³

et al. 2008

Journal of Clinical Epidemiology

View full text Add to dashboard Cite

Objective-To estimate the minimal clinically important difference (MCID) of seven measures of fatigue in rheumatoid arthritis.Study Design and Setting-A cross-sectional study design based on inter-individual comparisons was used. Six to eight subjects participated in a single meeting and completed seven fatigue questionnaires (nine sessions were organized and 61 subjects participated). After completion of the questionnaires, the subjects had five one-on-one 10-minute conversations with different people in the group to discuss their fatigue. After each conversation, each patient compared their fatigue to their conversational partner's on a global rating. Ratings were compared to the scores of the fatigue measures to estimate the MCID. Both non-parametric and linear regression analyses were used.Results-Non-parametric estimates for the MCID relative to "little more fatigue" tended to be smaller than those for "little less fatigue". The global MCIDs estimated by linear regression were: FSS 20.2, VT 14.8, MAF 18.7, MFI 16.6, CFS 9.9, RS 19.7, for normalized scores (0 to 100). The standardized MCIDs for the seven measures were roughly similar (0.67 to 0.76). Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Fatigue is a non-specific subjective symptom. In the absence of an objective measurement, fatigue can only be assessed by asking the subject. The measurement properties of available instruments need to be evaluated if they are to be used clinically or in clinical trials. Among the psychometric properties, longitudinal validity (responsiveness, sensitivity to change) is one of the most important. Closely related is the minimal clinically important difference (MCID), which is defined as "the smallest difference in score in the domain of interest (fatigue) which patients perceive as beneficial and which would mandate, in the absence of troublesome side effects and excessive cost, a change in the patient's management" [9]. The MCID is essential to interpret the magnitude of longitudinal changes or differences when comparing two treatments or different group of patients. Knowledge of MCID is also essential for meaningful sample size calculations in clinical trials. NIH Public AccessThe aim of our study was to estimate the MCID of seven validated self-administered measures of fatigue in persons with RA. The fatigue instruments identified from a literature review as suitable for use in RA and studied were: the Fatigue Severity Scale (FSS) [10,11] Patients and Methods PatientsThe study was conducted at the Mary Pack Arthritis Centre, Vancouver, Canada. All participants signe...

show abstract

Quality of life profiles in the first years of rheumatoid arthritis: Results from the EURIDISS longitudinal study

Cited by 35 publications

References 33 publications

Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis

Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis

The Relative Contribution of Domains of Quality of Life to Overall Quality of Life for Different Chronic Diseases

Determination of the minimal clinically important difference for seven fatigue measures in rheumatoid arthritis

Contact Info

Product

Resources

About